Skip to main content
logo
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
5.41
+0.28 (5.46%)
At close: Mar 9, 2026, 4:00 PM EDT
5.33
-0.08 (-1.48%)
After-hours: Mar 9, 2026, 5:10 PM EDT

Iovance Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
263.5164.071.19--
Revenue Growth (YoY)
60.60%13698.99%---
Cost of Revenue
173.1893.251.03--
Gross Profit
90.3270.820.16--
Selling, General & Admin
152.32152.27106.1104.183.66
Depreciation & Amortization Expenses
35.9437.621.42--
Research & Development
300.27276.23333.19294.78259.04
Other Operating Expenses
5.14----
Total Operating Expenses
493.67466.1460.72398.88342.7
Operating Income
-403.36-395.28-460.56-398.88-342.7
Interest Income
10.3120.2713.042.990.45
Total Non-Operating Income (Expense)
10.3120.2713.042.990.45
Pretax Income
-393.05-375.01-447.52-395.89-342.25
Provision for Income Taxes
-2.07-2.83-3.48--
Net Income
-390.98-372.18-444.04-395.89-342.25
Net Income to Common
-390.98-372.18-444.04-395.89-342.25
Shares Outstanding (Basic)
357290235159153
Shares Outstanding (Diluted)
357290235159153
Shares Change (YoY)
23.28%23.28%47.64%3.82%10.92%
EPS (Basic)
-1.09-1.28-1.89-2.49-2.23
EPS (Diluted)
-1.09-1.28-1.89-2.49-2.23
Free Cash Flow
-336.24-364.05-384.11-313.18-265.52
Free Cash Flow Per Share
-0.94-1.26-1.63-1.97-1.73
Gross Margin
34.28%43.17%13.12%--
Operating Margin
-153.08%-240.92%-38734.99%--
Profit Margin
-148.38%-226.84%-37345.42%--
FCF Margin
-127.61%-221.88%-32305.30%--
EBITDA
-356.03-347.21-427.43-377.74-328.72
EBITDA Margin
-135.12%-211.62%-35948.86%--
EBIT
-403.36-395.28-460.56-398.88-342.7
EBIT Margin
-153.08%-240.92%-38734.99%--
Effective Tax Rate
0.53%0.75%0.78%0.00%0.00%
Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q